This COVID-19 Vaccine Stock Has More to Offer
Pharmaceutical maker Pfizer (NYSE: PFE) is a longtime staple in the healthcare industry but has become tied to COVID-19 for its role as a vaccine supplier throughout the pandemic. The company's vaccine, developed with BioNTech, has added billions to its top and bottom lines, but investors must prepare for post-pandemic life as vaccine revenue fades over the coming years.
Pfizer's sales could shrink over the short term, but don't let that dissuade you from considering this blue-chip stock for your portfolio. The company's giant cash hoard gives the company several options to create value for shareholders. Here is what you might expect.
Pfizer's been in the pharmaceutical business a long time. With its $265 billion market capitalization, it is an industry behemoth, which doesn't typically happen in this industry without a combination of blockbuster drugs and acquisitions. Pfizer's made dozens of deals over the years, picking up debt along the way; you can see Pfizer's financial state below.
Source Fool.com
